ARTICLE | Company News
Avigen gene/cell therapy news
July 19, 2004 7:00 AM UTC
AVGN restructured and will reduce its workforce by 38 employees, or about 39%. The decision follows AVGN's May decision to discontinue development of its Coagulin B for hemophilia B in order to refocu...